Enel Health®Atlas
Sign in
Enel Health®Atlas
Browse libraries

Not medical advice. The Atlas is not a substitute for a clinician who can examine you.

Pancragen

Lys-Glu-Asp-Trp Pancreatic Bioregulator

Evidence grade 1 of 5, Untested. Read how the Atlas grades evidence.

Pancragen (KEDW / Lys-Glu-Asp-Trp) rests on preclinical work from the single Khavinson research network: in vitro human pancreatic cell cultures showing modulation of differentiation genes (PDX1, NGN3, PAX6, FOXA2, NKX2-2, NKX6.1, PAX4), a proposed DNA-binding mechanism at the ACCT promoter motif, rodent streptozotocin-diabetes models, and old-rhesus-monkey glucose-tolerance studies. The one human report is a small (about 33 type-2-diabetes patients plus 30 controls) uncontrolled, non-randomized, non-blinded single-center study; there are no registered ClinicalTrials.gov trials and no independent Western replication, so the honest grade is 1 (animal / in-vitro with unreplicated preliminary human observation), not 2.

FDA
Not approved by FDA (also not approved by EMA); no registered clinical trials; sold internationally as a research chemical 'not for human consumption,' and in Russia as a registered dietary supplement
WADA
Not specifically named on the WADA Prohibited List

Reference only. Not medical advice.

What can go wrong

No independent (non-Khavinson) replication, no registered RCTs, and no formal human toxicology, long-term safety, or pharmacokinetic data.

Talk to a clinician before taking this. The Atlas can tell you what has been studied about Pancragen. It cannot tell you how it would interact with your body, your history, or anything else you are taking, and nothing on this page is a reason to start.

A Khavinson tetrapeptide targeting pancreatic tissue and glucose-regulation gene expression in aging. Russian data only.

What people take it for

These are the reasons people give for taking it. They are not effects it has been shown to have.

  • Pancreatic aging (Russian data)
  • Glucose metabolism support

How it is supposed to work

Pancragen is a synthetic peptide (lysine, glutamic acid, aspartic acid, tryptophan) directed at the pancreas, promoted to support pancreatic and metabolic function in the bioregulator framework. Its organ-specific gene-regulation claim is unproven in rigorous human studies.

Pancragen is a synthetic short peptide, a defined-sequence second-generation bioregulator aimed at pancreatic tissue, part of the same organ-by-organ lineup as the heart peptide Cardiogen and the liver peptide Livagen.

Type
Synthetic short peptide
Target
Pancreas
Generation
Second (defined)
Use
Pulsed courses
Evidence
Preclinical and Russian
Western RCT
None

A Pancreas Bioregulator With Metabolic Claims And One Evidence Source

Pancragen follows the family pattern precisely. Its proposed action is the contested signature mechanism, peptide-driven gene regulation in the target tissue, here the pancreas, and that proposal is unestablished outside the originating group. The metabolic and insulin-related claims are preclinical and Russian, with no independent human trials, and metabolic disease, like cardiac disease, is a domain with effective proven treatments where unverified self-administration carries real downside. Pancragen is another tissue-labeled entry whose entire support comes from a single research lineage, attached to metabolic claims that the independent evidence base does not back.

Safety in detail

All efficacy and safety signals originate from the single Khavinson-affiliated research network. There are no formal toxicology, long-term safety, or pharmacokinetic studies, and the only human report is small, uncontrolled, and unblinded, so human safety is effectively uncharacterized.

  • Reported safety in decades of Russian clinical use is described as clean, with few serious adverse events, but that record comes largely from within the same research tradition that developed the peptides and has not been independently verified in Western trials.
  • Long-term safety in rigorous, controlled human studies is essentially uncharacterized outside that tradition.
  • Most material sold internationally is gray-market or supplement-grade, so unverified identity, dose and purity are the dominant practical risks.
  • Not FDA-approved for any use; claims of disease treatment are not supported by Western regulatory review.

Children and teenagers

Pancragen has no validated pediatric use and is an unapproved injected peptide. There is no appropriate pediatric use.

What people get wrong

Nothing recorded here yet. There is almost certainly something people get wrong about this one, and the blank space means we have not written it down, not that the record is clean.

Who profits, and who pushes back

Nobody is named here yet, because we have not done that work on this entry. Read that as unfinished. Somebody almost certainly sells this, and somebody almost certainly disputes it. Assume both until we have checked.

Pancragen reaches users only through the bioregulator gray market and longevity vendors. There is no approved product, and its market rests on the family’s reputation rather than metabolic evidence.

How we got here

Pancragen is a synthetic tetrapeptide, Lys-Glu-Asp-Trp (KEDW), developed by Vladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology as a short-peptide bioregulator, originally derived from work on peptide fractions isolated from bovine pancreatic tissue. It belongs to the same Khavinson tissue-specific bioregulator family as Epithalon (KE/AEDG, pineal), Vilon (KE), and the AEDL lung peptide, each proposed to bind gene-promoter motifs (KEDW at the ACCT sequence) and shift tissue-specific gene expression. Commercially it circulates two ways: in Russia as a registered dietary supplement within the Khavinson peptide product line, and internationally through research-chemical vendors that sell it as lyophilized 'Pancragen 20mg, not for human consumption.' It is unrelated to Epithalon despite this library's legacy id `epitalon-n`, which appears to be a placeholder mislabel rather than a description of the entry's actual content.

Pancragen was developed as a defined-sequence organ bioregulator at the St. Petersburg institute, extending Khavinson’s tissue-by-tissue approach to the pancreas.

The numbers behind the grade

Type
Peptide (Lys-Glu-Asp-Trp)
Target
Pancreas / metabolic
Russia
Bioregulator line
FDA
Not approved
Evidence
Single-tradition
Western RCTs
None

The people taking it

A pancreas-directed metabolic bioregulator within the Cytogen line, with a small following.

Pancragen’s users are longevity and metabolic-health enthusiasts and the bioregulator-protocol community.

Used as a pancreatic and metabolic bioregulator within Russian-tradition protocols; evidence is not independently validated.

Set against the alternatives

Pancragen is the pancreatic counterpart to the liver peptide Livagen and the heart peptide Cardiogen within the same system, and shares Epithalon’s longevity framing. Against genuinely evidence-based metabolic therapies, including the incretin drugs covered elsewhere in this library, its support is preclinical and single-lineage. That contrast with proven metabolic medicine is the key point.

What we do not know

  • Whether independent, Western randomized trials confirm any of the claimed clinical effects.
  • Whether the proposed DNA-binding, gene-regulating mechanism actually operates in human tissue at the doses used.
  • Why, after forty years and hundreds of papers, replication outside the originating institute remains so limited.
  • Whether results from complex tissue extracts (Cytomaxes) translate to the defined synthetic peptides (Cytogens) sold alongside them.

The market for this

What follows describes how this is bought and sold. It is not a buying guide and it is not an endorsement of any seller.

Available internationally as oral or injectable bioregulator supplements (Cytogen and Cytomax lines) and as research-use-only peptide vials, with legal status varying by country. None is an FDA-approved medicine, so there is no regulated US prescription route; the honest course is to treat the claims with caution and consult a clinician.

Material reaches international buyers two ways: as branded Cytogen (synthetic) or Cytomax (animal-tissue extract) supplements produced in Russia, and as research-use-only vials, much of it synthesized in China. Neither route guarantees the identity or potency the label claims, so an independent certificate of analysis is the only real check and is uncommon.

What this entry does not yet cover

What follows is unfinished work on our side, not a finding about Pancragen.

  • Timeline. We have not built the dated record of research and regulatory events.
  • Supply chain. We have not mapped where it is made.
  • What could change. No forward-looking summary yet.

Sources

The studies that matter

  • Khavinson group studies2000s

    Reported pancreatic and metabolic effects within the bioregulator research program.

  • Independent replicationnone notable

    No independent Western trials of Pancragen exist.